Your browser is no longer supported. Please, upgrade your browser.
ZIOPHARM Oncology, Inc.
Index- P/E- EPS (ttm)-0.39 Insider Own1.40% Shs Outstand213.96M Perf Week-4.68%
Market Cap495.69M Forward P/E- EPS next Y-0.44 Insider Trans0.00% Shs Float195.08M Perf Month-16.73%
Income-83.20M PEG- EPS next Q-0.12 Inst Own59.70% Short Float18.05% Perf Quarter-32.12%
Sales- P/S- EPS this Y45.60% Inst Trans0.05% Short Ratio20.81 Perf Half Y-38.29%
Book/sh0.49 P/B4.57 EPS next Y4.30% ROA-53.50% Target Price- Perf Year-28.89%
Cash/sh0.45 P/C4.95 EPS next 5Y- ROE-61.90% 52W Range2.06 - 5.95 Perf YTD-11.11%
Dividend- P/FCF- EPS past 5Y16.80% ROI- 52W High-62.35% Beta2.04
Dividend %- Quick Ratio5.90 Sales past 5Y- Gross Margin- 52W Low8.74% ATR0.14
Employees103 Current Ratio5.90 Sales Q/Q- Oper. Margin- RSI (14)34.32 Volatility5.85% 5.85%
OptionableYes Debt/Eq0.00 EPS Q/Q-10.00% Profit Margin- Rel Volume0.51 Prev Close2.30
ShortableYes LT Debt/Eq0.00 EarningsMay 06 AMC Payout- Avg Volume1.69M Price2.24
Recom2.40 SMA20-11.34% SMA50-19.83% SMA200-30.84% Volume857,011 Change-2.61%
Mar-12-21Downgrade Jefferies Buy → Hold $7 → $5
Mar-01-21Downgrade H.C. Wainwright Buy → Neutral
Jun-19-20Initiated Jefferies Buy $7
Mar-04-20Initiated Cantor Fitzgerald Overweight $6
Aug-23-19Resumed Raymond James Outperform
Apr-04-19Initiated Lake Street Buy $7
Apr-01-19Initiated Laidlaw Buy $7.50
Nov-15-18Upgrade Raymond James Mkt Perform → Outperform
Jun-18-18Downgrade JP Morgan Neutral → Underweight
Jun-01-17Initiated H.C. Wainwright Buy $9.50
Aug-10-16Upgrade Wells Fargo Underperform → Market Perform
Jul-19-16Reiterated Mizuho Neutral $7 → $5
Jun-02-16Initiated Raymond James Mkt Perform
May-11-16Reiterated Mizuho Neutral $6 → $7
Jan-25-16Reiterated Mizuho Neutral $10 → $6
Dec-04-15Initiated Wells Fargo Underperform
Jun-10-15Reiterated Mizuho Neutral $14 → $10
Mar-10-15Downgrade Mizuho Buy → Neutral $14
Mar-02-15Reiterated Mizuho Buy $11 → $14
Mar-20-14Initiated Mizuho Buy $11
Jun-22-21 07:10AM  
May-24-21 04:05PM  
May-19-21 04:05PM  
May-07-21 12:30PM  
May-06-21 04:02PM  
May-04-21 08:00AM  
Apr-29-21 09:00AM  
Apr-28-21 04:05PM  
Apr-19-21 08:00AM  
Apr-07-21 09:00AM  
Mar-23-21 10:19AM  
Mar-12-21 11:43AM  
Feb-26-21 12:22PM  
Feb-25-21 04:05PM  
Feb-16-21 04:01PM  
Feb-08-21 09:55AM  
Feb-05-21 12:00PM  
Jan-14-21 08:00AM  
Dec-23-20 04:01PM  
Dec-22-20 07:45AM  
Dec-21-20 04:01PM  
Dec-17-20 09:00AM  
Dec-16-20 04:01PM  
Dec-15-20 07:52AM  
Dec-14-20 04:02PM  
Dec-12-20 05:15PM  
Dec-11-20 06:57PM  
Dec-10-20 07:01PM  
Dec-08-20 09:00AM  
Dec-04-20 08:30AM  
Dec-02-20 10:04PM  
Nov-28-20 05:30PM  
Nov-27-20 05:32PM  
Nov-25-20 08:30PM  
Nov-24-20 09:00AM  
Nov-20-20 11:00AM  
Nov-19-20 09:30AM  
Nov-17-20 04:15PM  
Nov-16-20 08:30AM  
Nov-13-20 09:15AM  
Nov-12-20 09:00AM  
Nov-06-20 10:31PM  
Nov-05-20 04:02PM  
Nov-02-20 09:00AM  
Oct-29-20 09:00AM  
Oct-16-20 04:00PM  
Sep-30-20 06:26PM  
Sep-23-20 01:48PM  
Sep-22-20 08:30AM  
Sep-15-20 08:30AM  
Sep-14-20 04:17PM  
Sep-10-20 09:00AM  
Sep-07-20 09:58AM  
Aug-06-20 04:04PM  
Jul-28-20 09:00AM  
Jul-22-20 08:30AM  
Jul-10-20 07:25AM  
Jul-09-20 04:15PM  
Jul-08-20 08:30AM  
Jun-30-20 11:47PM  
Jun-22-20 09:48AM  
Jun-15-20 08:33AM  
Jun-12-20 09:00AM  
May-29-20 08:00AM  
May-27-20 04:15PM  
May-11-20 02:50PM  
May-08-20 04:00PM  
May-07-20 04:05PM  
Apr-30-20 08:00AM  
Apr-27-20 08:30AM  
Apr-06-20 06:00AM  
Mar-04-20 12:37PM  
Mar-02-20 04:05PM  
Feb-28-20 08:30AM  
Feb-24-20 08:30AM  
Feb-05-20 09:03AM  
Feb-04-20 04:01PM  
Jan-30-20 08:45AM  
ZIOPHARM Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing a portfolio of immuno-oncology therapies to treat patients with cancer. The company develops Sleeping Beauty platform, which is based on the non-viral genetic engineering of immune cells using a transposon/transposase system to engineer T-cells outside of the body for infusion; and Controlled IL-12 to stimulate expression of interleukin 12 or IL-12, a master regular of the immune system, in a controlled manner to focus the patient's immune system to attack cancer cells. Its product candidates include T cell receptor + T therapies to target solid tumors; chimeric antigen receptor + T cell therapies targeting CD19 for hematologic malignancies; and Ad-RTS-hIL-12 plus veledimex, a gene delivery system to regulate production of IL-12 to treat patients with recurrent glioblastoma multiforme in adults. The company has a license agreement with PGEN Therapeutics, Inc.; research and development agreement with The University of Texas MD Anderson Cancer Center; a patent license agreement with the National Cancer Institute; and a cooperative research and development agreement with the National Cancer Institute. ZIOPHARM Oncology, Inc. is headquartered in Boston, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Buck JillEVP, GM Gene TherapyJan 08Sale3.1227,89487,029199,516Jan 12 04:35 PM
Lafond Kevin GSVP, Treasurer & CAOJan 08Sale3.0918,02055,68263,965Jan 12 04:34 PM
Hadfield RobertGeneral Counsel and SecretaryJan 08Sale3.1226,50082,680133,319Jan 12 04:33 PM
De Groot EleanorEVP, GM Cell TherapyJan 04Sale2.7221,62058,806206,413Jan 06 05:03 PM
Cooper Laurence James NeilPresident and CEOJan 04Sale2.71105,693286,4281,799,280Jan 06 05:02 PM